Colon Cancer Stage III
13
5
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
38%
5 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer
Five-year Recurrence After LCME
Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery
The Sagittarius Trial
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
The Effects of Chiropractic in Adults With Colon Cancer
ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
Lymph Node Ratio and Kras Mutation in R Colon Cancer
Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C